Regulatory Gap: Why the FDA Can’t Keep Up With Pet Supplement Claims

Uncategorized · 7 min read

✓ Our Investigations Desk — July 30, 2026

Table of Contents

• Our Investigation
• Structural Limitations
• Jurisdictional Gaps
• International Comparison
• Proposed Reforms
• Frequently Asked Questions
• References

Our Investigation

Why do misleading pet supplement claims persist for months or years before enforcement? Our research desk analyzed the FDA’s structural capacity, jurisdictional boundaries, and enforcement mechanisms to understand why the regulatory system consistently fails to protect consumers from deceptive marketing.

Key Finding: The FDA’s inability to police pet supplement claims is not accidental — it is structural. The agency was not designed, funded, or authorized to proactively oversee a $2.4 billion market of 5,000+ products making thousands of individual claims.

Structural Limitations

Resource Allocation

The FDA’s Center for Veterinary Medicine (CVM) is responsible for:

• All animal drug approvals (new animal drug applications)
• Animal feed safety (including pet food)
• Animal dietary supplements
• Animal medical devices
• Antimicrobial resistance monitoring
• Import safety for animal products

CVM’s total budget is approximately $280 million annually, with roughly 1,500 full-time employees. The pet supplement segment — one of many responsibilities — receives a fraction of this already limited capacity.

The Pre-Market Void

Unlike animal drugs (which require FDA approval before sale), pet supplements require no pre-market review^[2]. A company can:

1. Formulate a product
2. Print labels with structure/function claims
3. Begin selling immediately
4. Never interact with the FDA unless a complaint triggers inspection

This means the FDA has no inventory of products on the market, no database of claims being made, and no mechanism to evaluate claims before consumers see them. The agency is structurally blind until something goes wrong.

Enforcement Capacity

As documented in our 5-year warning letter analysis, the FDA issues approximately 8-12 warning letters per year to pet supplement companies^[1]. Against an estimated 5,000+ active products making potentially non-compliant claims, this represents a detection and enforcement rate of well under 1%^[3].

Jurisdictional Gaps

The Food-Drug Boundary

Pet supplements exist in a jurisdictional gray zone:

• If classified as food: Subject to labeling requirements but no pre-market approval. Structure/function claims permitted without evidence.
• If classified as drug: Would require full NADA (New Animal Drug Application) approval — years of testing, millions of dollars.
• Current reality: Treated as food unless they make explicit disease claims, at which point they become “unapproved drugs” subject to enforcement.

This creates a perverse incentive: companies stay just below the drug-claim threshold (“supports joint health” rather than “treats arthritis”) to avoid drug regulation while still implying therapeutic benefit to consumers.

The FTC-FDA Divide

Advertising oversight is split:

• FDA: Regulates labeling (what is printed on the product)
• FTC: Regulates advertising (what is said in marketing, online claims, social media)

This split creates coordination challenges. A product may have compliant labeling (FDA jurisdiction) but deceptive online marketing (FTC jurisdiction). Neither agency has primary responsibility for the total consumer experience.

State vs Federal

State feed control officials^[4] (organized through AAFCO) have authority over animal feed and supplements sold within their states. However:

• State resources vary enormously (some states have 1-2 feed inspectors total)
• Online sales complicate jurisdiction (product sold from Utah to a consumer in Maine)
• State enforcement is primarily limited to labeling compliance, not marketing claims
• No state has a dedicated pet supplement oversight program

International Comparison

The U.S. model is the most permissive among developed nations. The EU model, by contrast, requires safety assessment by the European Food Safety Authority (EFSA) before any feed additive (including probiotics) can be marketed, and health claims require specific EFSA approval with supporting evidence.

Proposed Reforms

Consumer advocates and some legislators have proposed:

1. Mandatory product registration: Require all pet supplements to register with FDA before sale (similar to human supplement facility registration, but product-level)
2. Claim substantiation requirement: Require companies to have evidence supporting structure/function claims, available to FDA upon request
3. Adverse event reporting: Mandate reporting of adverse events (currently voluntary for most supplements)
4. Increased funding: Dedicated pet supplement oversight budget within CVM
5. Third-party testing mandate: Require batch testing by accredited laboratories with results available to regulators

Industry opposition to these proposals has been consistent and well-funded. The pet supplement industry spends an estimated $5-10 million annually on lobbying^[5] against increased regulation, primarily through trade associations. As we documented in our investigation of corporate ownership structures, the industry’s largest players have both the incentive and the resources to maintain the regulatory status quo.

Related Investigations

• FDA Warning Letters in Pet Supplements: A 5-Year Analysis
• When Supplements Go Wrong: FDA Recall Database Analysis
• NASC Quality Seal: What It Means and What It Doesn’t
• The Subscription Trap: Auto-Ship Practices in Pet Supplements